KRAS and neoplasm: We used SW620 metastatic colorectal cells, which have an activating mutation in K-Ras (G12V), mutations in the tumor suppressors SMAD4 (frameshift), p53 (R273H, P309S), and adenomatous polyposis coli (APC) (Q1338*), as well as MDA-MB-231 invasive breast metastatic cells, which have a different activating mutation in K-ras (G13D), a mutant B-Raf (G464V) and mutations in the tumor suppressors cyclin-dependent kinase inhibitor 2A (deletion), and p53 (R280K).